Publication date: Jul 08, 2026
Ferrer and Prilenia have initiated the confirmatory PRECISEHD study, a global phase 3 trial designed to evaluate the efficacy and safety of pridopidine in people living with Huntingtons disease. I hope the study will be well received by the community and that the recruitment goes as smoothly and fast as possible. The design aims to ensure appropriate assessment of any treatment effect compared with placebo. The primary endpoint is change from baseline to Week 52 in the combined Unified Huntingtons Disease Rating Scale score. EHA appreciate the involvement of the community in the preparations by consulting the patient organisations as well as HDCommunity Advisory Board. We experienced that Ferrer has taken the feedback very seriously when planning for the trial setup and followup.
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | Movement Disorders |
| disease | MESH | Huntington’s disease |
| disease | MESH | disease progression |
| drug | DRUGBANK | Pridopidine |